APLIF - Appili to get $10M from US DOD to advance potential biodefense vaccine ATI-1701

Appili Therapeutics (OTCQX:APLIF) will get $10M funding from the U.S. Department of Defense (DOD) to advance its biodefense vaccine candidate ATI-1701 to prevent infection with Francisella tularensis, a type of aerobic bacteria and the causative agent of tularemia. The company said the new funding is designed to replace and expand a prior contract awarded to one of its development partners. Appili will serve as prime contractor and oversee a development program for ATI-1701 that includes nonclinical, manufacturing, and regulatory activities to support an IND submission to the FDA for the drug to enter clinical trial. The award is subject to successful negotiations between the DOD's Joint Science and Technology Office of the Defense Threat Reduction Agency contracting division and Appili. The total funding amount will be confirmed upon contract execution. The company said Francisella tularensis has been classified as a Category A pathogen by the U.S. National Institutes of Health due to its high

For further details see:

Appili to get $10M from US DOD to advance potential biodefense vaccine ATI-1701